Chembio Diagnostics' DPP COVID-19 Antigen Test Approved In South Africa

by Vandana Singh, Benzinga Editor

November 29, 2021 9:37 AM | 1 min read |

South Africa Health Products Regulatory Authority (SAHPRA) has approved Chembio Diagnostics Inc's CEMI DPP SARS-CoV-2 Antigen test for use at the point of care.
The DPP SARS-CoV-2 Antigen test has been designed to detect SARS-CoV-2 antigens in only 20 minutes.
The antigen test uses a minimally invasive nasal swab and is designed to be read visually or with a DPP Micro Reader 2 optical analyzer.
The DPP SARS-CoV-2 Antigen test and the IgM/IgG Antibody test are authorized for import and distribution in South Africa by Chembio's distributor, Patient Focus Africa.
Related: Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test.
Price Action: CEMI shares are up 15% at $2.30 during the market session on Monday's last check.

Posted In: Long Ideas News Penny Stocks Health Care Movers Trading Ideas General Briefs COVID-19 Coronavirus Diagnostics

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.